David Lebovitz
Stock Analyst at Citigroup
(4.00)
# 578
Out of 4,641 analysts
89
Total ratings
65.57%
Success rate
7.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Lebovitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $382 → $371 | $202.48 | +83.23% | 3 | Aug 8, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $291 → $342 | $294.87 | +15.98% | 30 | Aug 2, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $38.42 | -1.09% | 1 | May 9, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $94 → $91 | $69.98 | +30.04% | 1 | Apr 25, 2024 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $68 | $58.40 | +16.44% | 1 | Mar 6, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $42.48 | -59.98% | 5 | Oct 27, 2023 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $111 → $92 | $84.40 | +9.00% | 6 | Feb 1, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $57 → $54 | $49.02 | +10.16% | 5 | Aug 4, 2021 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | $38 → $35 | $38.42 | -8.90% | 6 | May 6, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | $16 → $17 | $3.94 | +331.47% | 11 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $3.98 | +176.38% | 7 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $194 → $199 | $127.69 | +55.85% | 11 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $34 → $32 | $0.85 | +3,672.25% | 2 | Nov 3, 2020 |
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Buy
Price Target: $382 → $371
Current: $202.48
Upside: +83.23%
Alnylam Pharmaceuticals
Aug 2, 2024
Maintains: Buy
Price Target: $291 → $342
Current: $294.87
Upside: +15.98%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $38.42
Upside: -1.09%
BioMarin Pharmaceutical
Apr 25, 2024
Maintains: Neutral
Price Target: $94 → $91
Current: $69.98
Upside: +30.04%
Crinetics Pharmaceuticals
Mar 6, 2024
Initiates: Buy
Price Target: $68
Current: $58.40
Upside: +16.44%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $42.48
Upside: -59.98%
Blueprint Medicines
Feb 1, 2022
Maintains: Equal-Weight
Price Target: $111 → $92
Current: $84.40
Upside: +9.00%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57 → $54
Current: $49.02
Upside: +10.16%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38 → $35
Current: $38.42
Upside: -8.90%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16 → $17
Current: $3.94
Upside: +331.47%
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $3.98
Upside: +176.38%
Nov 13, 2020
Maintains: Overweight
Price Target: $194 → $199
Current: $127.69
Upside: +55.85%
Nov 3, 2020
Maintains: Overweight
Price Target: $34 → $32
Current: $0.85
Upside: +3,672.25%